Second-line Bevacizumab Plus Chemo Works in MBC
ISSUE: FEBRUARY, 2010
The first study to evaluate the addition of bevacizumab (Avastin, Genentech) to chemotherapy as second-line therapy for patients with metastatic breast cancer has revealed that the combination improves progression-free survival.
read more |
New Standard Suggested for Elderly MM Patients
ISSUE: FEBRUARY, 2010
A large two-part study has outlined a potential new standard for the treatment of multiple myeloma (MM) in elderly patients. On the basis of the study, induction therapy with bortezomib, melphalan and prednisone followed by maintenance with bortezomib and thalidomide appears to provide the best treatment sequence for MM in older patients.
read more |
Hematology News Sparks Excitement
ISSUE: FEBRUARY, 2010
Richard Stone, MD, highlights news from the American Society of Hematology meeting on acute leukemias, chronic myelogenous leukemia and myelofibrosis. Dr. Stone is director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, both in Boston.
read more |
Another Year of Belt Tightening
ISSUE: FEBRUARY, 2010
The 2010 regulatory changes from the Centers for Medicare & Medicaid Services have been released, and once again, oncology practices will be adversely impacted. Reimbursement trends continue their downward spiral for oncology.
read more |
1
